To mark Movember 2025, the Centre Baclesse is highlighting its renewed commitment to supporting prostate cancer patients. One year on from the launch of an innovative personalized treatment pathway, the Centre is asserting its pioneering role in clinical research with several trials underway, while stepping up its awareness-raising and information initiatives aimed at the general public and patients alike.
One year of innovative support for prostate cancer patients
Since November 2024, the Centre Baclesse has offered a personalized, multidisciplinary pathway dedicated to prostate cancer patients treated with second-generation hormone therapy. This unique pathway, organized as a day hospital, enables patients to meet in a single day with a complete team comprising a medical oncologist, a pathway nurse, a dietician, an adapted physical activity (APA) professional and a nurse specialized in oncosexology. Designed to optimize follow-up, improve treatment compliance and take into account side effects, it also aims to support patients in their overall quality of life, by addressing the physical, nutritional and psycho-social aspects of the care pathway.
Since its launch, 87 patients have benefited from this program. In September 2025, indications were even extended to all patients treated with hormone therapy, whether first- or second-generation. Prospects for 2026 include a neuro-cognition support project, as well as support for caregivers.
Therapeutic innovation and clinical trials underway at Centre Baclesse
The Centre Baclesse is also committed to therapeutic innovation, with three clinical trials underway:
- MK 2400-001: study of the efficacy of a conjugated antibody (ifinitamab deruxtecan) compared with conventional chemotherapy in patients with castration-resistant metastatic prostate cancer.
- PSMA Care study: comparison of LuPSMA treatment with or without hormone therapy in PET PSMA-positive patients.
- PEACE 6 Poor Responders: evaluation of the addition of LuPSMA in hormone-sensitive metastatic patients with suboptimal response to hormone therapy.
A video capsule
To further raise awareness, the Centre Baclesse has launched a video capsule entitled "Understanding hormone therapy for prostate cancer", available online since November 1, 2025 on the Centre Baclesse YouTube channel. This video capsule aims to simply explain the issues, benefits and side effects of hormone therapy, in order to support patients and their loved ones in their care journey.
An event not to be missed
On Tuesday, November 25, 2025, at 6:30 p.m., the J.S. Abbatucci amphitheater at the Baclesse Center will host a theatrical reading of the play "Radicale," a comedy that tackles masculinity, illness, and relationships with humor and sensitivity, written and directed by David FRISZMAN ( La Clef des Planches theater company). "Radicale" is a lighthearted comedy about a serious subject: prostate cancer. Through three actors, the play explores masculinity, illness, and relationships with humor and sensitivity.
The show will be followed by a discussion with the onco-urology team at the Centre Baclesse and the Cerhom association.
Registration is free but mandatory (registration link).
This unique moment, combining humor and dialogue, invites us to talk about men's health in a different way during Movember.
